Labels psychiatry

Yatham, L.N., Liddle, P. F. Dennie, J. (1999). Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment a positron emission tomography study with fluorine-18-labeled setoperone. Arch. Gen. Psychiatry, 56, 705-11. 

Si, T. M., Shu, L., Yu, X. et al. (2005a). The efficacy and safety of citalopram in treatment of depression a multi-center open-label study. Chinese Journal of Psychiatry, 38(4), 222-6. 

Alonso, M., Val, E. Rapaport, M. H. (1997). An open-label study of SSRI treatment in depressed Hispanic and non-Hispanic women. /. Clin. Psychiatry, 58, 31. 

Gillin J. C., Smith-Vaniz A., Schnierow B. et al. (2001). An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder. J. Clin. Psychiatry 62, 789-96. 

Pomerantz, Jay M., Stan N. Finkelstein, Ernst R. Berndt, Amy W. Poret, Leon E. Walker, Robert C. Alber, Vidya Kadiyam, Mitali Das, David T. Boss, and Thomas H. Ebert. 2004. Prescriber Intent, Off-Label Usage, and Early Discontinuation of Antidepressants. Journal of Clinical Psychiatry 65(3) 395-404. 

Benjamin J, Ben-Zion IZ, Karbofsky E, Dannon P (2000) Double-blind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology (Berl) 149 194-196 Berlant J, van Kammen DP (2002) Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder a preliminary report. J Clin Psychiatry 63 15-20... 

Rauch, S.L., Jenike, M.A., Alpert, N.M., Baer, L., Breiter, H.C., Savage, C.R., and Fischman, A.J. (1994) Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 51 62-70. 

Kumra S., Jacobsen, L.K., Lenane, M., Karp, B.I., Frazier, J.A., Smith, A.K., Bedwell, J., Lee, R, Malanga, C.J., Hamburger, S., and Rapoport, J.L. (1998) Childhood-onset schizophrenia an open-label study of olanzapine in adolescents. / Am Acad Child Adolesc Psychiatry 37 377-385. 

McDougle, C.J., Holmes, J.P., Bronson, M.R., Anderson, G.M., Volkmar, F.R., Price, L.H., and Cohen, D.J. (1997) Risperidone treatment of children and adolescents with pervasive developmental disorders a prospective, open-label study. / Am Acad Child Adolesc Psychiatry 36 685-693. 

Buitelaar, J.K., van der Gaag, R.J., and van der Hoeven, J. (1998) Buspirone in the management of anxiety and irritability in children with pervasive developmental disorder results of an open-label study. / Clm Psychiatry 59 56—59. 

Ambrosini, P.J., Wagner, K.D., Biederman, J., Click, I., Tan, C., Elia, J., Hebeler, J., Rabinovich, H., Lock, J., and Geller, D. (1999) Multicenter open-label sertraline study in adolescent outpatients with major depression. J Am Acad Child Adolesc Psychiatry 38 566-572. 

Strober, M., DeAntonio, M., Schmidt-Lackner, S., Pataki, C., Freeman, R., Rigali, J., and Rao, U. (1999) The pharmacotherapy of depressive illness in adolescents an open-label comparison of fluoxetine with imipramine-treated historical controls. / Clin Psychiatry 60 164-169. 

Apter, A., Ratzoni, G., King, R., Weizman, A., lancu, I., Binder, M., and Riddle, M. (1994) Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. J Am Acad Child Adolesc Psychiatry 33 342-348. 

Rosenbetg, D.R., Stewatt, C.M., Fitzgetald, K.D., Tawile, V., and Cattoll, E. (1999) Patoxetine open-label tteatment of pediattic outpatients with obsessive-compulsive disotdet. / Am Acad Child Adolesc Psychiatry 38 1180-1185. 

Budman, C.L., Gayer, A., Lesser, M., Shi, Q., and Bruun, R.D. (2001) An open-label study of the treatment efficacy of olanzapine for Tourette s disorder. / Clin Psychiatry 62 290—294. 

King, B.H., Wright, M., Snape, M., and Dourish, C.T. (2001b) Case series amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities. / Am Acad Child Adolesc Psychiatry 40 654—657. 

Marangeh LB, Johnson CR, Kertz B, et al Olanzapine in the treatment of apathy in previously depressed participants maintained on SSRIs an open label, flexible-dose study. J Clin Psychiatry 63 391-395, 2002... 

Kratochvil CJ, Heiligenstein JH, Dittmann R, et al Atomoxetine and methylphenidate treatment in children with ADHD a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41 776-784, 2002... 

Csernansky JG, Lombrozo L, Gulevich GD, et al. Treatment of negative schizophrenic symptoms with alprazolam a preliminary open-label study. J Clin Psychopharmacol 1984 4 349-352. Douyon R, Angrist B, Peselow E, et al. Neuroleptic augmentation with alprazolam clinical effects and pharmacokinetic correlates. Am J Psychiatry 1989 146 231-234. 

Weiss EL, Potenza MN, McDougle CJ, et al. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors an open-label case series. J Clin Psychiatry 1999 60 524-527. 

Ambrosini PJ, Wagner KD, Biederman J, et al. Multicenter open label sertraline study in adolescent outpatients with major depression. J Am Acad Child Adolesc Psychiatry 1999 38 566-572. 

Kumar S, Jacobson LK, Lenane M, et al. Childhood onset schizophrenia an open label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998 37 377-385. 

Rosenthal M (2003) Tiagabine for the treatment of generalized anxiety disorder a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 64 1245-1249... 

Krakow B, Johnston L, Melendrez D, Hollifield M, Warner TD, Chavez-Kennedy D, Herlan MJ (2001) An open-label trial of evidence-based cognitive behavior therapy for nightmares and insomnia in crime victims with PTSD. Am J Psychiatry 158 2043-2047... 

Koran, L. M., Chuong, H. W., Bullock, K. D., Smith, S. C. 2003, Citalopram for compulsive shopping disorder an open-label study followed by double-blind discontinuation, J.Clin.Psychiatry, vol. 64, no. 7, pp. 793-798. 

Meyer, J. H., Houle, S., Sagrati, S., Carella, A., Hussey, D. F., Ginovart, N., Goulding, V., Kennedy, J., Wilson, A. A. 2004, Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography effects of major depressive episodes and severity of dysfunctional attitudes, Arch.Gen.Psychiatry, vol. 61, no. 12, pp. 1271-1279. 

This is consistent with my testimony and publications, beginning with Toxic Psychiatry in 1991, in which I warned about both suicide and violence caused by SSRIs and with my book Medication Madness (in press), which will present dozens of case histories illustrating harm to self and to others induced by the SSRIs. The FDA continues to lag behind, however, mentioning hostility and aggression in the new labels as problems associated with SSRIs but without giving these dire outcomes sufficient emphasis. 

---